Key Takeaways NVO's semaglutide sales have slowed amid pricing pressure and rising GLP-1 competition.GPCR's aleniglipron hit key phase IIb goals with up to 15.3% placebo-adjusted weight loss.Novo Nordisk is advancing CagriSema, cagrilintide, amycretin, and monlunabant to defend its lead.Novo Nordisk (NVO) is a dominant player in the cardiometabolic space, marketing its blockbuster semaglutide-based (GLP-1) drugs — Ozempic (for diabetes) and Wegovy (for obesity). Despite being NVO’s key growth drivers, sales ...